BPC-157 side effects: what human studies do and do not show

Why there is no reliable side-effect list

The available research cannot show how risk changes with the way BPC-157 enters the body or with how long it is used.

A few small reports in people exist. Some reported no adverse events during limited observation. FDA also found a handful of adverse-event reports that are difficult to interpret. An adverse event is a health problem reported after exposure.

A report alone does not prove that the product caused the problem. Neither kind of finding settles safety. A study may find no harm for several reasons.

The product may be tolerable, or too few people may be observed. Follow-up may be brief, monitoring may be narrow, or an uncommon event may not occur in that sample.

Studies in people have not shown enough about how BPC-157 affects people. Products sold as BPC-157 can also differ in chemical form, ingredients, purity, sterility, storage, and even identity. That leaves two safety questions: what BPC-157 does in people, and what the specific product contains.

• No FDA-approved BPC-157 drug product
• No dependable rate for adverse effects
• Not enough data on long-term use or interactions with other substances
• No proof that a consumer vial matches the product studied

Why online side-effect lists overstate the evidence.

Search results often list headache, nausea, fatigue, dizziness, injection-site reactions, or other symptoms as though BPC-157 had an established prescribing label. BPC-157 has no such label. A conventional drug label can summarize adverse reactions because defined products were tested in described groups of people.

Those studies used structured monitoring and counted how many people were exposed. BPC-157 has no record of that kind.

A symptom in a personal story is a signal. It gives no estimate of how often the symptom occurs and does not show that the product caused it. A spontaneous adverse-event report has the same limit.

The event followed a reported exposure, but other products, illnesses, timing, missing details, or product-quality problems may explain it. An empty report database would also not prove safety, especially where reporting is incomplete.

What human studies actually included.

The clearest recent safety publication observed two adults. Each person received two brief intravenous infusions. Researchers checked vital signs and laboratory tests and followed both people through the next day.

The authors reported no side effects or measured abnormalities. Both participants had received intravenous BPC-157 before entering the study.

The two-person study had no comparison group and detected no problem during its short follow-up. It was too small and brief to show common side effects, rare harms, delayed effects, or risks from repeated use. That result applies to those two people and that way of giving the product.

Another small study included 12 women with interstitial cystitis, a bladder condition. They received BPC-157 injections in the bladder wall during one procedure. The study had no comparison group, and no adverse events were reported.

It was too small, specific, and brief to establish safety for other uses. It does not show safety for oral, nasal, under-skin, or self-administered products.

FDA staff's July 2026 pre-meeting review found five small clinical studies using BPC-157. They included short rectal-enema studies, a small knee-pain report, the bladder pilot, and the two-person intravenous pilot.

FDA staff noted short durations, small samples, early study designs, limited safety details, and unclear monitoring in most of those studies. Older meeting abstracts reported headache and flatulence in enema research. The record is not sufficient to establish those as a complete or measured side-effect profile.

What FDA adverse-event reports can and cannot show.

FDA's 2026 briefing describes three reports linked to injectable products labeled BPC-157. The first described redness and swelling. The second described shortness of breath and an emergency-room visit.

The last described skin-color changes after a multi-peptide product. Each report lacked important details or had other possible causes, and two involved another peptide. The reports do not show that BPC-157 caused the events.

The reports still deserve attention. One involved breathing difficulty, and a repeated reaction can strengthen concern about a product. The reports cannot show how often an event occurs or prove an effect of the molecule itself. They also cannot show how many exposed people had no event.

FDA also notes that traditional 503A compounders generally do not report adverse events to the agency. For compounded BPC-157, the reporting system is therefore an incomplete record of how often events occur.

What FDA has reviewed

BPC-157 is not a component of an FDA-approved drug. FDA's public compounding-risk page says compounded products containing BPC-157 may raise concerns about unwanted immune responses for certain routes. The page also describes problems with peptide-related impurities and with how the active ingredient is characterized.

The agency says it has no or only limited safety information for proposed routes. It lacks enough information to know whether administration would cause harm.

For the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA staff evaluated BPC-157 free base and acetate as bulk substances for a proposed ulcerative-colitis use. The staff briefing found clinical safety information insufficient and the substances not fully described. It concluded that available evidence weighed against adding them to the section 503A bulks list.

On July 23, the advisory committee voted 8 to 6, with one abstention, to recommend adding the BPC-157-related substances to that list. Advisory-committee recommendations are nonbinding. The vote did not approve a BPC-157 drug or create an FDA-reviewed prescribing label. It also did not itself complete the rulemaking needed to change the 503A bulks list.

The August 2 review did not confirm an FDA final rule implementing the recommendation.

Lack of approval does not prove that BPC-157 has no effect on the body. FDA has not approved any BPC-157 product after reviewing its evidence, manufacturing, and label for a defined use. The phrases “Made by a pharmacy,” “prescribed by a clinician,” and “research use only” do not change that approval status.

Product quality can add risks.

A published study describes one material, made, formulated, stored, and given under a protocol. An online vial, clinic preparation, capsule, or nasal spray needs its own evidence unless equivalence is demonstrated. FDA's review found inconsistent naming for proposed BPC-157 bulk substances and dosage forms. It also found gaps in the information needed to establish identity, purity, quality, stability, and delivery characteristics.

Peptides can clump together (aggregate) or contain impurities from manufacturing and breakdown. FDA identifies possible unwanted immune responses linked to aggregation and peptide-related impurities for some routes. A certificate with a single purity percentage does not by itself establish sequence identity, impurity characterization, or potency over time. It also does not establish sterility, endotoxin control, container compatibility, or equivalence to a clinical-study product.

Sterility is a separate question for anything intended to be sterile. FDA explains that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing. Poor compounding can lead to contamination or incorrect strength.

That statement does not mean every compounded product is contaminated. The BPC-157 literature still cannot answer quality questions about a specific facility or lot, and those questions can materially change risk.

• Exact sequence and chemical form
• Manufacturer or compounder and applicable oversight
• Identity, potency, impurity, sterility, and endotoxin testing
• Formulation, container, storage, route, and time in use
• Evidence that the tested lot matches the product discussed

Animal studies do not close the human safety gap.

Much of BPC-157's visibility comes from cell and animal work in tendon, muscle, gastrointestinal, vascular, and other injury models. A frequently cited tendon paper studied rat tendon tissue and cultured tendon cells (explants and fibroblasts). It reported signals for outgrowth, survival, and migration.

Those findings can support a preclinical repair hypothesis. They do not show that BPC-157 heals a human injury, and they do not define human adverse effects.

Safety findings do not automatically transfer from animals to people. An apparent benefit in an animal model does not test safety. FDA's 2026 review found the nonclinical toxicology too limited in scope and duration to inform safety for the proposed human uses and routes.

Possible pathways involving blood vessels, nitric-oxide signaling, or other processes raise questions for toxicology and clinical research. The record does not support claims that BPC-157 causes or prevents a particular human disease.

Online cancer concerns sit at the same point in the record. A pathway linked to new blood-vessel growth is not evidence that BPC-157 causes cancer in people. The current record in people also cannot establish that it does not. Cancer risk, tumor interactions, and safety in people with active or prior cancer (malignancy) remain open questions, with no settled warning or reassurance.

Long-term effects and interactions remain unknown.

The reviewed sources do not show enough about long-term use, repeated courses, withdrawal effects, or harm that builds up over time. They also do not show how the body absorbs, moves, changes, and removes BPC-157 for the forms promoted online. Those forms include oral, under-skin, nasal, and skin products.

Without these data, researchers cannot reliably predict how much reaches the body, when the amount peaks, or how long it remains. They also cannot tell how the route (how it enters the body) changes risk.

No adequate drug-interaction program in people has tested BPC-157 with anticoagulants, antiplatelet drugs, anti-inflammatory drugs, hormones, cancer therapies, immune-modifying drugs, supplements, alcohol, or other peptides. A missing interaction report does not show that no interaction exists. With several products used together, an effect may come from one ingredient, an interaction, contamination, or the combined product.

Safety also cannot be confirmed for pregnancy, breastfeeding, children, or older adults as a population. The same applies to people with liver or kidney impairment, immune disorders, bleeding risk, or cancer, and to people preparing for surgery. The very small published samples cannot represent these groups. A clinician's familiarity with peptide marketing cannot replace product-specific evidence, a complete medication review, and a plain account of what remains unknown.

How to check a safety claim

A seller may call BPC-157 well tolerated. The study behind that claim should name the product tested, how it was used, who took part, and for how long. It should also list the comparison group and the safety checks.

A two-person study, an animal experiment, and a large study with a comparison group carry different weight. A registered study without results has no findings to check.

ClinicalTrials.gov currently returns two BPC-157 interventional records. An older Phase 1 record on safety and how the body handles the drug (pharmacokinetics) has no posted results and lists unknown status. A newer randomized Phase 2 hamstring-strain trial is recruiting and has no posted results as of this review.

A registration records a plan. It supplies no result and does not make a product generally available, effective, or safe.

Anyone who develops difficulty breathing, facial or throat swelling, fainting, a severe whole-body reaction, or signs of infection after an injection needs prompt medical assessment. Do not use this article or any online side-effect comparison to decide whether a serious reaction can wait. Product and adverse-event details can also be reported through FDA MedWatch. The article gives no dosing, reconstitution, injection, sourcing, or individualized treatment instructions.

As reviewed in August 2026, small studies in people do not establish BPC-157's safety. Product contents and quality add uncertainty. Important risks, including interactions and long-term effects, remain unmeasured, and personal stories cannot measure them.